Novavax exec says its new COVID shot should work against variants on rise
Gaithersburg: Novavax Inc's head of research and development has said an updated COVID-19 vaccine the company is already producing is likely to be protective against other fast-growing coronavirus variants circulating in the U.S.
Protein-based vaccines like Novavax's take longer to produce than the messenger RNA-based (mRNA) versions made by Moderna and Pfizer/ BioNTech.
Because of that, the company said earlier this year it had begun producing a version of the vaccine to target the currently dominant XBB.1.5 variant of the virus at commercial scale.
A panel of outside advisers to the U.S. Food and Drug Administration is scheduled to meet on June 15 to discuss strain selection for this year's COVID-19 booster shots, and regulators are expected to make their decision shortly afterward.
Novavax R&D chief Filip Dubovsky in an interview made the case for the XBB.1.5-targeting vaccine, saying it was a good approach that should also provide protection against related variants on the rise, such as XBB.2.3.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.